Idogen AB:製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8293)
◆英語タイトル:Idogen AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8293
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:29
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Idogen AB (Idogen) is a biotechnology company that develops tolerogenic vaccines which reprogram the immune system of paitents. The company provides product portfolio such as antibodies for autoimmune diseases, organ rejection after transplantation and several other disease conditions. It develops anti-drug antibodies against critical treatment with coagulation factor VIII (factor VIII). Idogen utilizes its platform technology to facilitate the development of tolerogenic vaccines in several areas such as hemophilia A, rheumatoid arthritis, and transplantation for type-1 diabetes. The company technology comprises a small number of dendritic cells and is treated with zebularine and the disease specific antigens. It carries out collaboration with Oxford University to develop novel therapeutic strategies for the treatment of rheumatoid arthritis. Idogen is headquartered in Lund, Sweden.

Idogen AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Idogen AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Idogen AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Idogen AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Idogen AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Idogen AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Idogen AB, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Idogen Enters into Research Agreement with Advinus Therapeutics 10
Idogen Enters into Agreement with University of Oxford 11
Idogen Partners with Karolinska Institutet 12
Equity Offering 13
Idogen to Raise up to USD6 Million in Rights Offering of Units 13
Idogen Raises USD2 Million in IPO 14
Acquisition 15
HCN Group Acquires Minority Stake in Idogen from LU Holding 15
Idogen AB – Key Competitors 16
Idogen AB – Key Employees 17
Idogen AB – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Financial Announcements 19
Aug 21, 2018: Idogen: Interim report January – June 2018 19
Apr 24, 2018: Idogen Reports Q1 2018 Financial Results 20
Feb 15, 2018: Idogen: Year-end report 1 January – 31 December 2017 21
Corporate Communications 23
Apr 25, 2018: Idogen Names Hanne Risager Romedahl As Chief Scientific Officer 23
Mar 31, 2017: Idogen recruits Chief Medical Officer 24
Product News 25
Aug 17, 2018: Idogen extends the project portfolio to projects in autoimmune diseases 25
05/18/2017: Idogen has been granted EUR 2.9 million funding from Horizon 2020 26
05/11/2017: Tolerogenic vaccine for kidney transplantation to be next therapeutic area for Idogen 27
Product Approvals 28
Jan 16, 2017: Orphan drug designation formally granted for Idogen in Europe 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Idogen AB, Pharmaceuticals & Healthcare, Key Facts 2
Idogen AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Idogen AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Idogen AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Idogen AB, Deals By Therapy Area, 2012 to YTD 2018 8
Idogen AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Idogen Enters into Research Agreement with Advinus Therapeutics 10
Idogen Enters into Agreement with University of Oxford 11
Idogen Partners with Karolinska Institutet 12
Idogen to Raise up to USD6 Million in Rights Offering of Units 13
Idogen Raises USD2 Million in IPO 14
HCN Group Acquires Minority Stake in Idogen from LU Holding 15
Idogen AB, Key Competitors 16
Idogen AB, Key Employees 17

List of Figures
Idogen AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Idogen AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Idogen AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Idogen AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Idogen AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Idogen AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Idogen AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Idogen AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Idogen AB:製薬・医療:M&Aディール及び事業提携情報(Idogen AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆